This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamel, O. W. Articles by Meyer, J. S. Search for Related Content PubMed PubMed Citation Articles by Kamel, O. W. Articles by Meyer, J. S.

American Journal of Pathology, Vol 134, 107-113, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Thymidine labeling index and Ki-67 growth fraction in lesions of the breast

OW Kamel, WA Franklin, JC Ringus and JS Meyer
Department of Pathology, University of Chicago, IL 60637.

Thymidine labeling index (TLI) and Ki-67 growth fraction (KGF) are two indicators of proliferative activity in breast cancer. The authors examined the relationship between TLI and KGF in 36 breast lesions (28 invasive ductal carcinomas and 8 benign lesions). TLI and KGF values were determined in separately labeled tissue sections as well as in frozen tissue sections labeled with both Ki-67 and tritiated thymidine. In separately labeled sections of carcinoma mean TLI was 6.8 while mean KGF was 16.0. For double-labeled sections of carcinoma mean TLI and KGF values were 6.1 and 16.4, respectively. Strong correlation between TLI and KGF of malignant tumors was found by both methods: r = 0.90 (P less than 0.001) for separately labeled sections, and r = 0.96 (P less than 0.001) for double-labeled sections. In double-labeled sections of benign lesions strong correlation between TLI and KGF also was observed (r = 0.94, P less than 0.001); however, in separately labeled benign breast tissue there was no significant correlation between TLI and KGF (r = 0.38). This may have been the result of variable sampling of small proliferative foci in separate sections of benign breast tissue. The strong correlation between TLI and KGF in breast carcinoma suggests that KGF may have prognostic implications similar to those of the TLI.

This article has been cited by other articles:

				R. L. Keith, Y. E. Miller, R. M. Gemmill, H. A. Drabkin, E. C. Dempsey, T. C. Kennedy, S. Prindiville, and W. A. Franklin Angiogenic Squamous Dysplasia in Bronchi of Individuals at High Risk for Lung Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1616 - 1625. [Abstract] [Full Text]

				J. Chang, T. J. Powles, D. C. Allred, S. E. Ashley, A. Makris, R. K. Gregory, C. K. Osborne, and M. Dowsett Prediction of Clinical Outcome from Primary Tamoxifen by Expression of Biologic Markers in Breast Cancer Patients Clin. Cancer Res., February 1, 2000; 6(2): 616 - 621. [Abstract] [Full Text]

				J. Chang, T. J. Powles, D. C. Allred, S. E. Ashley, G. M. Clark, A. Makris, L. Assersohn, R. K. Gregory, C. K. Osborne, and M. Dowsett Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3058 - 3063. [Abstract] [Full Text] [PDF]

				F. C. Schmitt and M. P. Ferreira MIB-1 Is a Suitable Marker of Proliferative Activity in Formalin-fixed, Paraffin-embedded Sections of Breast Cancer International Journal of Surgical Pathology, April 1, 1995; 2(4): 287 - 293. [Abstract] [PDF]